These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291 [TBL] [Abstract][Full Text] [Related]
4. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer. Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533 [TBL] [Abstract][Full Text] [Related]
5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
6. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women. Chishti U; Aziz AB J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567 [TBL] [Abstract][Full Text] [Related]
7. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379 [TBL] [Abstract][Full Text] [Related]
8. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272 [TBL] [Abstract][Full Text] [Related]
9. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354 [TBL] [Abstract][Full Text] [Related]
10. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991 [TBL] [Abstract][Full Text] [Related]
12. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. Octeau D; Kessous R; Klein K; Kogan L; Pelmus M; Ferenczy A; Greenwood CMT; Van Kempen LC; Salvador S; Lau S; Tonin PN; Yasmeen A; Gotlieb WH Mol Cancer Res; 2019 Dec; 17(12):2422-2431. PubMed ID: 31530633 [TBL] [Abstract][Full Text] [Related]
13. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes. Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194 [TBL] [Abstract][Full Text] [Related]
14. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K; J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients. Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342 [TBL] [Abstract][Full Text] [Related]
17. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485 [TBL] [Abstract][Full Text] [Related]
18. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals. Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049 [TBL] [Abstract][Full Text] [Related]
19. Ten genes for inherited breast cancer. Walsh T; King MC Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821 [TBL] [Abstract][Full Text] [Related]
20. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]